Advanced Enzyme Technologies Approves Share Buyback, Acquires Remaining Stake in JCB and Funds ANPL
Advanced Enzyme Technologies Limited announced several significant corporate actions following its Board Meeting held on August 08, 2026. The company approved the acquisition of the remaining stake in JC Biotech Private Limited (JCB), a step set to make JCB a Wholly Owned Subsidiary, while also sanctioning a large-scale share buyback and planned funding for Advanced Nutrazyme Private Limited (ANPL).The Board approved the Buyback of fully paid-up equity shares at a price not exceeding ? 500 per equity share. The maximum size set for this transaction is t 697,000,000, which could account for up to 1,394,000 Equity Shares, representing 1.24% of the existing paid-up equity capital.
The company also approved the acquisition of the remaining stake, amounting to 4.28% of equity shares in JC Biotech Private Limited (JCB). The transaction for JCB is planned through a cash consideration totaling ? 79.79 million at a price of ? 90 per Equity Share. Upon completion of this acquisition, JCB will become a Wholly Owned Subsidiary of the company.
In terms of corporate investment, the Board approved an infusion of additional funds not exceeding ? 20 million into Advanced Nutrazyme Private Limited (ANPL). This funding may occur in one or more tranches and can be provided through Equity investment or by providing inter corporate deposit.
Financial Highlights for Quarter Ended June 30, 2026
The Board reviewed and approved the Un-audited Consolidated Financial Results of the company for the quarter ended June 30, 2026. The consolidated results show Total Income reaching 2,028.09 million. For the period, Net profit for the company was reported at 385.89 million, and total comprehensive income attributable to shareholders stood at 356.66 million.The following table summarizes key financial metrics for the quarter ended June 30, 2026:
| Metric | Amount (million) |
|---|---|
| Total Income | 2,028.09 |
| Net Profit for the Period | 385.89 |
| Total Comprehensive Income Attributable to Shareholders | 356.66 |
Operational and Strategic Details
The company’s operations are focused solely on the manufacturing and sales of enzymes across one business segment.The acquisition details for JCB confirm that it is a pharmaceutical entity, incorporating in 1991. The last three years turnover for JCB were ? 728 million (FY 26), ? 600 million (FY 25) and ? 627 million (FY 24).
Advanced Nutrazyme Private Limited (ANPL), a Wholly Owned Subsidiary, is involved in the nutrition and wellness sector and was incorporated on July 04, 2025. The company has plans to use the infused funds for its general corporate purposes and business development.
ADVENZYMES Stock Price Movement
Advanced Enzyme Technologies Limited saw its shares slip by 1.79% on Friday, settling at ₹324.35 after trading in a volatile session. The stock traded within the intraday range of ₹322 to ₹332, with 177,783 shares recorded in the final exchange.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.